Journal article
Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction: VEGF gene therapy for myocardial infarction
Journal of controlled release, v 93(2), pp 175-181
05 Dec 2003
PMID: 14636723
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: We used a novel lipopolymeric gene delivery system, TeplexDNA, to transfect myocardium with plasmid vascular endothelial growth factor-165 (pVEGF) and evaluated the ability of pVEGF to preserve left ventricular function and structure after coronary ligation in a rabbit model.
Methods: New Zealand white rabbits underwent circumflex coronary ligation after direct intramyocardial injection of either Terplex alone or Terplex+50 μg pVEGF-165. Serial echocardiography and histologic studies were performed (
n=12/group). Mortality did not differ between groups. The data is reported as the mean±standard deviation.
Results: Over the 21 days following coronary ligation, pVEGF-165-treated animals demonstrated significant improvement in fractional shortening (20–25%,
p=0.02), long axis two-dimensional ejection fraction (42–51%,
p=0.02) and short axis m-mode ejection fraction (46–54%,
p=0.02). No significant improvements were noted in the control group. VEGF-treated animals had a 50% increase in peri-infarct vessel density and a trend towards a smaller infarct size (20% vs. 29%,
p=0.10). In animals receiving pVEGF-165, the diastolic ventricular area increased from 1.87±0.24 cm
2 prior to ligation to 2.19±0.23 cm
2 at 21 days following ligation, compared to an increase from 1.84±0.38 to 2.54±0.55 cm
2 over the same period in control animals (
p=0.03). Similarly, the systolic ventricular area in VEGF-165 animals increased from 1.06±0.26 cm
2 prior to ligation to 1.50±0.29 cm
2 at 21 days following ligation, compared to an increase from 1.16±0.30 to 1.86±0.43 cm
2 over the same period in the control animals (
p=0.04).
Conclusion: TerplexDNA mediated delivery of plasmid VEGF administered at the time of coronary occlusion improves left ventricular function and reduces left ventricular dilation following myocardial infarction.
Metrics
Details
- Title
- Effect of Terplex/VEGF-165 gene therapy on left ventricular function and structure following myocardial infarction: VEGF gene therapy for myocardial infarction
- Creators
- David A. Bull - University of UtahStephen H. Bailey - University of UtahJeffrey J. Rentz - University of UtahJames S. Zebrack - University of UtahMinhyung Lee - University of UtahSheldon E. Litwin - University of UtahSun Wan Kim - University of Utah
- Publication Details
- Journal of controlled release, v 93(2), pp 175-181
- Publisher
- Elsevier
- Number of pages
- 7
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- Cardiothoracic Surgery
- Web of Science ID
- WOS:000187625400008
- Scopus ID
- 2-s2.0-0242494165
- Other Identifier
- 991021960812504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Web of Science research areas
- Chemistry, Multidisciplinary
- Pharmacology & Pharmacy